Marshall Edwards Licenses the Investigational Anti-Cancer Compound NV-128 From Novogen Limited
August 05, 2009 08:05 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - August 5, 2009) - Novogen Limited (ASX: NRT) (NASDAQ: NVGN) and Marshall Edwards, Inc. (NASDAQ: MSHL) have
concluded a license agreement for...
Independent Data Monitoring Committee Reviews Marshall Edwards, Inc.'s Arrangements for Data Analysis of the Ovature Trial
June 17, 2009 08:30 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - June 17, 2009) - The Independent Data Monitoring Committee
(IDMC) created to oversee the conduct of the Phase III OVArian TUmor
REsponse (OVATURE) Trial, which convened...
Marshall Edwards, Inc., to Undertake Analysis of Ovature Trial
April 14, 2009 08:20 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - April 14, 2009) - Marshall Edwards,
Inc., (NASDAQ: MSHL) today announced that it will be undertaking an
un-blinded analysis of the data from its...
Board Changes at Novogen Limited Announced
March 23, 2009 10:46 ET
|
Novogen, Limited
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - March 23, 2009) - Novogen Limited (ASX: NRT) (NASDAQ: NVGN) is pleased to announce the appointment of Mr. William
D. Rueckert to its Board of...
Biotech Analyst Joins Board of Directors of Marshall Edwards, Inc.
March 19, 2009 13:07 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - March 19, 2009) - Marshall Edwards, Inc.
(NASDAQ: MSHL) is pleased to announce the appointment of Leah Cann to the
Board of Directors of the...
Yale Researchers Present Results of Phase II Phenoxodiol Clinical Trial in Prostate Cancer Patients at ASCO 2009 Genitourinary Cancers Symposium
February 24, 2009 08:00 ET
|
Marshall Edwards, Inc.
ORLANDO, FL--(Marketwire - February 24, 2009) - Marshall Edwards, Inc. (NASDAQ: MSHL) --
Preliminary results from a Phase II clinical trial of oral phenoxodiol in
patients with prostate cancer to be...
Marshall Edwards, Inc. to Present at the 27th Annual JPMorgan Healthcare Conference
January 14, 2009 08:59 ET
|
Marshall Edwards, Inc.
WASHINGTON, DC--(Marketwire - January 14, 2009) - Marshall Edwards, Inc. (NASDAQ: MSHL) will
present at the 27th Annual JPMorgan Healthcare Conference in San Francisco
on Thursday January 15, 2008 at...
Marshall Edwards, Inc. Granted IND for Triphendiol
January 07, 2009 08:10 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - January 7, 2009) - Marshall Edwards, Inc. (NASDAQ: MSHL) today
announced that it has been granted an Investigative New Drug (IND) approval
by the United States Food and...
Marshall Edwards, Inc. Announces Resignation of Stephen Breckenridge From Board of Directors and Appointment of William Rueckert as Chairman of Audit Committee
December 19, 2008 08:15 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - December 19, 2008) - Marshall Edwards, Inc. (NASDAQ: MSHL)
announced that Stephen Breckenridge resigned as a member of the Board of
Directors effective December 15, 2008...
Marshall Edwards, Inc. Files IND Application for Triphendiol
December 01, 2008 08:10 ET
|
Marshall Edwards, Inc.
NEW CANAAN, CT--(Marketwire - December 1, 2008) - Marshall Edwards, Inc. (NASDAQ: MSHL) today
announced that it has filed an application with the United States Food and
Drug Administration for an...